Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.
Alzheimer's disease
blood biomarkers
immuno-infrared sensor
risk stratification
single molecule array
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
revised:
29
05
2022
received:
25
02
2022
accepted:
10
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
20
7
2022
Statut:
aheadofprint
Résumé
Blood-based biomarkers for Alzheimer's disease (AD) are urgently needed. Here, four plasma biomarkers were measured at baseline in a community-based cohort followed over 17 years, and the association with clinical AD risk was determined. Amyloid beta (Aβ) misfolding status as a structure-based biomarker as well as phosphorylated tau 181 (P-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentration levels were determined at baseline in heparin plasma from 68 participants who were diagnosed with AD and 240 controls without dementia diagnosis throughout follow-up. Aβ misfolding exhibited high disease prediction accuracy of AD diagnosis within 17 years. Among the concentration markers, GFAP showed the best performance, followed by NfL and P-tau181. The combination of Aβ misfolding and GFAP increased the accuracy. Aβ misfolding and GFAP showed a strong ability to predict clinical AD risk and may be important early AD risk markers. Aβ misfolding illustrated its potential as a prescreening tool for AD risk stratification in older adults.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Greenblatt C, World Health Organization. Dementia. [September 28, 2021]; Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dementia. 2018;14(4):535-562.
Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020;217(11):e20200861.
Li D, Mielke MM. An update on blood-based markers of Alzheimer's disease using the SiMoA platform. Neurol Ther. 2019;8(2):73-82.
Fyfe I. Neurofilament light chain - new potential for prediction and prognosis. Nat Rev Neurol. 2019;15(10):557.
Leuzy A, Cullen NC, Mattsson-Carlgren N, Hansson O. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Curr Opin Neurol. 2021;34(2):266-274.
Hansson O, Cullen N, Zetterberg H, Blennow K, Mattsson-Carlgren N. Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Ann Clin Transl Neurol. 2021;8(1):259-265.
Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dementia. 2021;18(6):1141-1154.
Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022.
Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78(4):396-406.
Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain. 2021;144(1):325-339.
Ashton NJ, Leuzy A, Lim YM, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Commun. 2019;7(1):1-11.
Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1):3555.
Cullen NC, Zetterberg H, Insel PS, et al. Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Ann Clin Transl Neurol. 2020;7(9):1661-1673.
Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034-1042.
Verberk IMW, Thijssen E, Koelewijn J, et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12(1):118.
Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382.
Bateman RJ, Barthelemy NR, Benzinger TL, et al. Mass spectrometry measures of plasma Aβ, tau and P-tau isoforms’ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer's disease. Alzheimers Dementia. 2020;16(S5):e037518.
Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e1659.
Nabers A, Ollesch J, Schartner J, et al. Amyloid-β-Secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: a biomarker candidate for Alzheimer's disease. Anal Chem. 2016;88(5):2755-2762.
Nabers A, Ollesch J, Schartner J, et al. An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids. J Biophotonics. 2016;9(3):224-234.
Nabers A, Hafermann H, Wiltfang J, Gerwert K. Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease. Alzheimers Dementia (Amst). 2019;11:257-263.
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
Jarrett JT, Berger EP, Lansbury PT. The C-terminus of the beta protein is critical in amyloidogenesis. Ann NY Acad Sci. 1993;695:144-148.
Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018;10(5).
Stockmann J, Verberk IMW, Timmesfeld N, et al. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2020;12(1):1-13.
Stocker H, Nabers A, Perna L, et al. Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors. Alzheimers Dementia. 2020;16(2):283-291.
Hadjichrysanthou C, Evans S, Bajaj S, et al. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. Alzheimers Research Ther. 2020;12(1):74.
de WolfF, M Ghanbari, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain. 2020;143(4):1220-1232.
Rajan KB, Aggarwal NT, McAninch EA, et al. Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol. 2020;88(6):1065-1076.
Saum K-U, Dieffenbach AK, Jansen EHJM, et al. Association between oxidative stress and frailty in an elderly German population: results from the ESTHER cohort study. Gerontology. 2015;61(5):407-415.
Perna L, Wahl HW, Weberpals J, et al. Incident depression and mortality among people with different types of dementia: results from a longitudinal cohort study. Soc Psychiatry Psychiatr Epidemiol. 2019;54(7):793-801.
Stocker H, Perna L, Weigl K, et al. Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Mol Psychiatry 2020;26(10):5812-5822.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia. 2011;7(3):263-269.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde Deutsche Gesellschaft für Neurologie Springer-Verlag GmbH. S3-Leitlinie Demenzen. 1st ed. Springer; 2017.
DGPPN Deutsche Gesellschaft f Neurologie Springer-Verlag GmbH. S3-Leitlinie Demenzen. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017.
Stocker H, Beyer L, Perna L, et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: results from a prospective cohort followed over 17 years. Alzheimers Dementia. 2022;1-11. https://doi.org/10.1002/alz.12614
Beyer L, Günther R, Koch JC, et al. TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2021;8(1):271-277.
Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dementia. 2021;00:1-14. https://doi.org/10.1002/alz.12510
Schafer JL. Analysis of Incomplete Multivariate Data (1st ed.): Chapman and Hall/CRC. 1997.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.
Zhao LN, Long H, Mu Y, Chew LY. The toxicity of amyloid β oligomers. Int J Mol Sci. 2012;13(6):7303-7327.
Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25(2):277-283.
Weston PSJ, Poole T, O'Connor A, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimers Res Ther. 2019;11(1):19.
Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481-488.
Zetterberg H. Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases. J Neurol Neurosurg Psychiatry. 2021;92(12):1253.
Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry. 2021;11(1):27.
Nguyen K, Rabenstein DL, Interaction of the Heparin-binding consensus sequence of β-amyloid peptides with heparin and heparin-derived oligosaccharides. J Phys Chem B 2016;120(9):2187-2197.